12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Avastin bevacizumab: Phase II data

The open-label, international Phase II RTOG 0615 trial in 44 evaluable patients with stage IIB-IVB nasopharyngeal cancer showed that Avastin plus cisplatin, radiation therapy and fluorouracil led to estimated 2-year PFS and OS rates of 74.7% and 90.9%, respectively, at a median follow-up of 2.5 years. Additionally, estimated 2-year locoregional progression-free and distant...

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >